ריקסתון - Rixathon

Rixathon is indicated for the following indications: * Non-Hodgkin’s lymphoma (NHL): Rixathon is indicated for the treatment of patients with relapsed or refractory low-grade or follicular, B-cell non-hodgkin’s lymphoma. Rixathon is indicated for the treatment of previously untreated patients with low-grade or follicular lymphoma in combination with chemotherapy.Rixathon is indicated for the treatment of patients with CD20 positive diffuse large B-cell non-Hodgkin's lymphoma in combination with CHOP chemotherapy. Rixathon maintenance therapy is indicated for the treatment of follicular lymphoma patients responding to induction therapy. * Chronic lymphocytic leukaemia (CLL): Rixathon in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. Only limited data are available on efficacy and safety for patients previously treated with monoclonal antibodies including Rixathon or patients refractory to previous Rixathon plus chemotherapy.* Granulomatosis with polyangiitis and Microscopic polyangiitis: Rixathon, in combination with glucocorticoids, is indicated for the treatment of adult patients with Granulomatosis with polyangiitis (GPA) (Wegener’s Granulomatosis (WG) and Microscopic polyangiitis (MPA).*pemphigus vulgaris (PV):Rixathon is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris (PV)